Biodesix (NASDAQ:BDSX) Director Purchases $236,000.00 in Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler purchased 20,000 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The shares were acquired at an average cost of $11.80 per share, with a total value of $236,000.00. Following the completion of the purchase, the director directly owned 1,563,210 shares in the company, valued at $18,445,878. The trade was a 1.30% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Biodesix Price Performance

BDSX opened at $9.66 on Friday. The business has a fifty day moving average of $7.88 and a 200 day moving average of $7.76. The stock has a market cap of $76.89 million, a P/E ratio of -1.74 and a beta of 0.60. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 41.11. Biodesix, Inc. has a 52-week low of $3.44 and a 52-week high of $21.60.

Biodesix (NASDAQ:BDSX) last released its earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share for the quarter, topping the consensus estimate of ($1.60) by $0.44. The business had revenue of $21.77 million during the quarter, compared to the consensus estimate of $20.98 million. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%. As a group, sell-side analysts anticipate that Biodesix, Inc. will post -0.35 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Aberdeen Group plc bought a new stake in Biodesix during the fourth quarter valued at about $1,784,000. Oracle Investment Management Inc. purchased a new stake in shares of Biodesix during the third quarter valued at about $113,000. Millennium Management LLC bought a new stake in shares of Biodesix in the 3rd quarter valued at about $113,000. Finally, XTX Topco Ltd grew its position in shares of Biodesix by 99.4% in the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares during the last quarter. 20.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BDSX. Wall Street Zen raised shares of Biodesix from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Biodesix in a report on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Biodesix presently has a consensus rating of “Moderate Buy” and an average price target of $32.50.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.